Product Name: ErbB2-pY877
Product Number: AB-PK125
Size: 25 µg      Price:89.00
      $US
Target Full Name: Receptor protein-tyrosine kinase ErbB2 Tyr-877 phosphosite

Target Alias: CD340; C-erbB-2; EC 2.7.10.1; Epidermal growth factor receptor-related protein; ErbB2; HER2; HER2; HER-2; Kinase ErbB2; MLN 19; MLN19; NEU; Neu; NEU proto-oncogene; NGL; P185erbB2; Receptor protein-tyrosine kinase erbB-2; Receptor protein-tyrosine kinase erbB-2 precursor; Tyrosine kinase-type cell surface receptor HER2; V-erb-b2 erythroblastic leukemia viral oncogene 2, neuro/glioblastoma derived oncogene; V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

Product Type Specific: Phosphosite-specific polyclonal antibody for human ErbB2 Y877 phosphosite

Antibody Code: PK125

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: Y877

Protein UniProt: P04626

Protein SigNET: P04626

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Ig Isotype Clone: IgG

Antibody Immunogen Source: Peptide with amino acid sequence surrounding human ErbB2 Tyr-877 phosphosite (Thr-Glu-pTyr-His-Ala)

Antibody Immunogen Sequence: TEpYHA

Antibody Immunogen Description: 5 amino acid phosphopeptide corresponding to the human ErbB2 Y877 phosphosite

Production Method: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

Antibody Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol

Storage Conditions: -20°C

Storage Stability: > 1 year

Product Use: Western blotting, Immunohistochemistry (IHC)

Antibody Dilution Recommended: 2 µg/mL

Antibody Potency: Very strong

Antibody Species Reactivity: Human, Mouse, Rat

Antibody Positive Control: Y877 phosphorylated ErbB2

Antibody Specificity: Very high

Antibody Cross Reactivity: No strong cross-reactivities with other proteins.

Related Product 1: ErbB2 pan-specific antibody (Cat. No.: AB-NK054-3)

Related Product 2: ErbB2 pan-specific antibody (Cat. No.: AB-NK054-4P)

Related Product 3: ErbB2-2 pan-specific antibody (Cat. No.: AB-NK054-5)

Related Product 4: ErbB2-3 pan-specific antibody (Cat. No.: AB-NK054-6)

Related Product 5: ErbB2-4 pan-specific antibody (Cat. No.: AB-NK054-7)

Related Product 6: ErbB2-pY1248 phosphosite-specific antibody (Cat. No.: AB-PK613)

Related Product 7: ErbB2-pY735 phosphosite-specific antibody (Cat. No.: AB-PK614)

Related Product 8: ErbB2-pY877 phosphosite-specific antibody (Cat. No.: AB-PK615)

Related Product 9: ErbBSubtide - ErbB2 protein kinase substrate peptide

Scientific Background: ErbB2 is a receptor-tyrosine kinase of the EGFR family, which apparently needs a coreceptor for ligand binding. It is an essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. It is not directly activated by EGF, TGF- alpha and amphiregulin, although GP30 is a potential ligand for this receptor. Upon ErbB2 activation, the MEMO1-RHOA-DIAPH1 signalling pathway elicits the phosphorylation and inhibition of GSK3B at cell membrane. This prevents the phosphorylation of CLASP2 and APC, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. The tyrosine-phosphorylated ErbB2 receptor also interacts with PIK3C2B, PRKCABP, MUC1, GRB7, ERBB2IP, Src, KPNB1, RANBP2, EEA1, CRM1, CLTC, PTK6, RPA94 and ACTB. ErbB2 is amplified in ~30% of breast cancer and the overexpression induces constitutive activity, which correlates with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. Inhibitors of ErbB2 include Herceptin, lapatinib, PKI-166, EKB-569, and CI-1033. Four alternatively spliced human isoforms of ErbB2 have molecular masses of 137,910, 136,501, 70,917 and 62,568 Da.
Figure 1. Immunoblotting of various cell lines with AB-PK125 antibody at a 500 X dilution. The target protein ErbB2 is indicated. Each lane was loaded with 15 µg of cell lysate protein. The max signal count was 36612.


Figure 2. Immunoblotting of various cell lines with AB-PK121 antibodyat a 500 X dilution. The target protein ErbB2 is indicated. Each lane was loaded with 15 µg of cell lysate protein. The max signal count was The max signal count was 31796.


References

[1] Miyagawa S, Katsu Y, Watanabe H, Iguchi T. Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol. Oncogene. 2004 Jan 15;23(2):340-9. PMID: 14647453.

[2] Dittadi R, Gion M. More about: prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst. 2000 Sep 6;92(17):1443-4. PMID: 10974087.

[3] Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 1999 Oct;19(10):6845-57. PMID: 10490623.

[4] Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1500-4. PMID: 7509075.